Multitarget Strategy for Primary Podocytopathies

Launched by FONDAZIONE IRCCS CA' GRANDA, OSPEDALE MAGGIORE POLICLINICO · Dec 2, 2024

Keywords

ClinConnect Summary

This clinical trial is looking at a specific kidney condition called nephrotic syndrome, particularly focusing on primary podocytopathies, which are diseases affecting special cells in the kidneys that help filter blood. The researchers want to see if they can find a factor in the blood of affected patients that causes proteinuria, which means too much protein is leaking into the urine. They will also test a new combined therapy to see if it helps treat this condition. To do this, they will compare blood and urine samples from patients with these kidney issues to samples from healthy individuals and those with other kidney diseases.

If you're considering participating in this trial, you might be eligible if you have been diagnosed with certain types of primary podocytopathies or other related kidney diseases. Participants will visit the clinic regularly for up to three years, where they will provide blood and urine samples, and possibly a sample from a specific treatment procedure called plasmapheresis. It's important to know that certain individuals, such as those in remission or with severe kidney function issues, may not be eligible. Overall, the trial aims to better understand these kidney diseases and explore new treatment options.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Signature of informed consent for study participation
• * One of the following conditions:
• • 1. Patients with primary podocytopathies (with a histological diagnosis of FSGS or MCD) showing clinical and/or histological evidence of post-transplant recurrence.
• • 2. Patients with primary podocytopathies (with a histological diagnosis of FSGS or MCD) without clinical and/or histological evidence of post-transplant recurrence.
• • 3. Patients with primary podocytopathies in their native kidneys in an active clinical phase of the disease.
• • 4. Patients with podocytopathies presenting clinical features compatible with a secondary form due to another condition.
• • 5. Patients with glomerulonephritis other than primary podocytopathies (e.g., IgA nephropathy, systemic lupus erythematosus, membranous nephropathy).
• • 6. Patients with no history of renal diseases
• Exclusion Criteria:
• • Subjects affected by primary podocytopathies or other glomerulonephritides in clinical remission or with ESRD (eGFR \< 15 ml/min) and/or on renal replacement therapy
• • Individuals unable to understand and consent to the study procedures
• • Any clinical condition that, according to the investigator's judgment, could compromise patient safety during study participation